MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tarsus Pharmaceuticals, Inc

< Previous 1 2 Next >
News headline image
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Participate at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Announces Pricing of $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Present at the Jefferies Global Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
News headline image
Tarsus Added to NASDAQ Biotechnology Index
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers IBB TARS
News headline image
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story